Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
The objective of this study is to investigate the bioequivalence of Mylan\'s alendronate sodium 10 mg tablets to Merck\'s Fosamax 10 mg tablets following a single, oral 40 mg (4 x 10 mg) dose administration under fasting conditions.
Epistemonikos ID: aa37455db0facdafededa3560ccabd8fa650b3dd
First added on: May 05, 2024